Cargando…

Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma

SIMPLE SUMMARY: In the last years, targeted therapy and immunotherapy modified the landscape for metastatic melanoma treatment. These therapeutic approaches led to an impressive improvement in patients overall survival. Unfortunately, the emergence of drug resistance and side effects occurring durin...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Martile, Marta, Garzoli, Stefania, Ragno, Rino, Del Bufalo, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565555/
https://www.ncbi.nlm.nih.gov/pubmed/32948083
http://dx.doi.org/10.3390/cancers12092650
_version_ 1783595959788240896
author Di Martile, Marta
Garzoli, Stefania
Ragno, Rino
Del Bufalo, Donatella
author_facet Di Martile, Marta
Garzoli, Stefania
Ragno, Rino
Del Bufalo, Donatella
author_sort Di Martile, Marta
collection PubMed
description SIMPLE SUMMARY: In the last years, targeted therapy and immunotherapy modified the landscape for metastatic melanoma treatment. These therapeutic approaches led to an impressive improvement in patients overall survival. Unfortunately, the emergence of drug resistance and side effects occurring during therapy strongly limit the long-term efficacy of such treatments. Several preclinical studies demonstrate the efficacy of essential oils as antitumoral agents, and clinical trials support their use to reduce side effects emerging during therapy. In this review we have summarized studies describing the molecular mechanism through which essential oils induce in vitro and in vivo cell death in melanoma models. We also pointed to clinical trials investigating the use of essential oils in reducing the side effects experienced by cancer patients or those undergoing anticancer therapy. From this review emerged that further studies are necessary to validate the effectiveness of essential oils for the management of melanoma. ABSTRACT: The last two decades have seen the development of effective therapies, which have saved the lives of a large number of melanoma patients. However, therapeutic options are still limited for patients without BRAF mutations or in relapse from current treatments, and severe side effects often occur during therapy. Thus, additional insights to improve treatment efficacy with the aim to decrease the likelihood of chemoresistance, as well as reducing side effects of current therapies, are required. Natural products offer great opportunities for the discovery of antineoplastic drugs, and still represent a useful source of novel molecules. Among them, essential oils, representing the volatile fraction of aromatic plants, are always being actively investigated by several research groups and show promising biological activities for their use as complementary or alternative medicine for several diseases, including cancer. In this review, we focused on studies reporting the mechanism through which essential oils exert antitumor action in preclinical wild type or mutant BRAF melanoma models. We also discussed the latest use of essential oils in improving cancer patients’ quality of life. As evidenced by the many studies listed in this review, through their effect on apoptosis and tumor progression-associated properties, essential oils can therefore be considered as potential natural pharmaceutical resources for cancer management.
format Online
Article
Text
id pubmed-7565555
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75655552020-10-26 Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma Di Martile, Marta Garzoli, Stefania Ragno, Rino Del Bufalo, Donatella Cancers (Basel) Review SIMPLE SUMMARY: In the last years, targeted therapy and immunotherapy modified the landscape for metastatic melanoma treatment. These therapeutic approaches led to an impressive improvement in patients overall survival. Unfortunately, the emergence of drug resistance and side effects occurring during therapy strongly limit the long-term efficacy of such treatments. Several preclinical studies demonstrate the efficacy of essential oils as antitumoral agents, and clinical trials support their use to reduce side effects emerging during therapy. In this review we have summarized studies describing the molecular mechanism through which essential oils induce in vitro and in vivo cell death in melanoma models. We also pointed to clinical trials investigating the use of essential oils in reducing the side effects experienced by cancer patients or those undergoing anticancer therapy. From this review emerged that further studies are necessary to validate the effectiveness of essential oils for the management of melanoma. ABSTRACT: The last two decades have seen the development of effective therapies, which have saved the lives of a large number of melanoma patients. However, therapeutic options are still limited for patients without BRAF mutations or in relapse from current treatments, and severe side effects often occur during therapy. Thus, additional insights to improve treatment efficacy with the aim to decrease the likelihood of chemoresistance, as well as reducing side effects of current therapies, are required. Natural products offer great opportunities for the discovery of antineoplastic drugs, and still represent a useful source of novel molecules. Among them, essential oils, representing the volatile fraction of aromatic plants, are always being actively investigated by several research groups and show promising biological activities for their use as complementary or alternative medicine for several diseases, including cancer. In this review, we focused on studies reporting the mechanism through which essential oils exert antitumor action in preclinical wild type or mutant BRAF melanoma models. We also discussed the latest use of essential oils in improving cancer patients’ quality of life. As evidenced by the many studies listed in this review, through their effect on apoptosis and tumor progression-associated properties, essential oils can therefore be considered as potential natural pharmaceutical resources for cancer management. MDPI 2020-09-16 /pmc/articles/PMC7565555/ /pubmed/32948083 http://dx.doi.org/10.3390/cancers12092650 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Di Martile, Marta
Garzoli, Stefania
Ragno, Rino
Del Bufalo, Donatella
Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma
title Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma
title_full Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma
title_fullStr Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma
title_full_unstemmed Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma
title_short Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma
title_sort essential oils and their main chemical components: the past 20 years of preclinical studies in melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565555/
https://www.ncbi.nlm.nih.gov/pubmed/32948083
http://dx.doi.org/10.3390/cancers12092650
work_keys_str_mv AT dimartilemarta essentialoilsandtheirmainchemicalcomponentsthepast20yearsofpreclinicalstudiesinmelanoma
AT garzolistefania essentialoilsandtheirmainchemicalcomponentsthepast20yearsofpreclinicalstudiesinmelanoma
AT ragnorino essentialoilsandtheirmainchemicalcomponentsthepast20yearsofpreclinicalstudiesinmelanoma
AT delbufalodonatella essentialoilsandtheirmainchemicalcomponentsthepast20yearsofpreclinicalstudiesinmelanoma